

FOR IMMEDIATE RELEASE

Press Contact: Ariadne Genomics Natalia Alexandrova Ariadne Genomics natal@ariadnegenomics.com Tel: 240-453-6296 **Press Contact: Murex Pharmaceuticals** Kathryn Goldstein Levenson & Brinker PR kathryn.goldstein@levensonbrinkerpr.com Tel 214-932-6066

Murex Pharmaceuticals Licenses Ariadne's PathwayStudio[®] Software Solution To Be Utilized For Cancer Therapeutics Development

ROCKVILLE, Md. - July 27, 2006 - Ariadne Genomics, Inc. today announced that Murex Pharmaceuticals (Dallas, Texas) has licensed its PathwayStudio[®] software solution for the visualization and analysis of biological pathways and gene regulation networks. Murex will use Pathway Studio to develop computer-based models for the identification and validation of cancer targets.

PathwayStudio (formerly known as PathwayAssist) enables life scientists to identify relationships among proteins, small molecules, cell processes and treatments, and automatically extract relevant biological interactions from scientific literature. With the product's resident ResNet database of over 1,000,000 interactions extracted from PubMed and approximately 1000 predefined pathways, researchers can easily reconstruct regulatory networks from their microarray and proteomics data, identify biomarkers, and model drug responses.

"It's hard to overestimate the importance of PathwayStudio in our development of cancer therapies based on patients' individual gene expression data," commented David Shanahan, President and CEO of Murex Pharmaceuticals. "PathwayStudio will accelerate our development efforts as well as help to further increase the safety of our products".

"PathwayStudio is a must-have tool for cancer target research," added Ilya Mazo, President of Ariadne. "The software keeps the on-board ResNet database up-to-date, automatically extracting relevant biological interactions from literature, while the flexible user interface allows database queries to expand known pathways and build regulatory networks focused on specific research tasks, such as drug target or biomarker discovery."

PathwayStudio is available as a desktop or workgroup solution. A 20 day fully functional trial version can be found on the Ariadne website at <u>www.ariadnegenomics.com</u>.

About Murex Pharmaceuticals

Murex Pharmaceuticals is a privately held biotechnology company dedicated to developing cancer therapies based on an individual's tumor biology. The company is headquartered in Dallas, Texas, with

research and development efforts underway at labs in Boston, Massachusetts, Carrollton, Texas, and San Francisco, California.

About Ariadne

Ariadne develops systems biology software for life science research. Products include PathwayStudio[®] (formerly PathwayAssist) leading pathway analysis software and PathwayExpertTM informatics platform for the research of cellular regulation and drug response modeling. Ariadne software is equipped with MedScanTM, a mature information extraction technology based on domain-specific natural language processing (NLP), and comes with a ResNet family of molecular network databases, both automatically generated and manually curated. MedScan ReaderTM is a biomedical literature browser that greatly facilitates the reading of scientific text by automatically extracting and displaying the information of interest.

###